Two compounds (celecoxib and valdecoxib) from the diarylheterocycle class of cyclooxygenase inhibitors were radiolabeled and used to characterize their binding to cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), several single-point variants of COX-2 (Val523Ile, Tyr355Ala, Arg120Ala, Arg120Gln, Arg120Asn) and one triple-point variant of COX-2 [Val523Ile, Arg513His, Val434Ile (IHI)]. We demonstrate highly specific and saturable binding of these inhibitors to COX-2. Under the same assay conditions, little or no specific binding to COX-1 could be detected. The affinity of [ 3 H]celecoxib for COX-2 (K D ϭ 2.3 nM) was similar to the affinity of [ 3 H]valdecoxib (K D ϭ 3.2 nM). The binding to COX-2 seems to be both rapid and slowly reversible with association rates of 5.8 ϫ 10 6 /M/min and 4.5 ϫ 10 6 /M/min and dissociation rates of 14 ϫ 10 Ϫ3 /min (t 1/2 ϭ 50 min) and 7.0 ϫ 10 Ϫ3 /min (t 1/2 ϭ 98 min) for [ 3 H]celecoxib and [ 3 H]valdecoxib, respectively. These association rates increased (4-to 11-fold) when the charged arginine residue located at the entrance to the main hydrophobic channel was mutated to smaller uncharged amino acids (Arg120Ala, Arg120Gln, and Arg120Asn). Mutation of residues located within the active site of COX-2 that define a 'side pocket' (Tyr355Ala, Val523Ile, IHI) of the main channel had a greater effect on the dissociation rate than the association rate. These mutations, which modified the shape of and access to the 'side pocket', affected the binding affinity of [
pocket within the active site. Moreover, the isoleucine/valine difference at position 523 of COX-1/COX-2 seems to contribute significantly to the COX-2 selectivity of members of a new class of inhibitors, diarylheterocycles (e.g., celecoxib, ) . Replacement of Val523 in COX-2 with isoleucine (Val523Ile) slows the time-dependent inhibition produced by some members of the diarylheterocycle class Guo et al., 1996; Wong et al., 1997) . The Ile523 of COX-1 seems to make the side pocket more restrictive and possibly less accessible than in COX-2.
Although specific residues important for binding have been identified, the relative contribution of these residues to the kinetics of binding of the diarylheterocycle class has not been determined. Using a fluorescent diarylheterocyclic oxazole, Lanzo et al. (2000) measured the kinetic rate constants for binding of this oxazole to native COX-1 and COX-2 by fluorescence quenching. Furthermore, some elegant attempts have been made using a mathematical model to discern the kinetic rate constants for inhibitor binding to COX-1 and COX-2 (Callan et al., 1996; So et al., 1998) . In general, studies have suggested that the slow dissociation of the diarylheterocyclic inhibitors from COX-2 accounts for their selectivity. In this study, using radiolabeled celecoxib and valdecoxib, we provide a kinetic analysis of the binding of these two diarylheterocyclic compounds to COX-1, COX-2, and several COX-2 variants.
Materials and Methods
Materials. Hemin, indomethacin, naproxen, mefenamic acid, ibuprofen, and piroxicam were purchased from Sigma Chemical Co. (St. Louis, MO). Nimesulide and meloxicam were prepared in-house by the Searle Medicinal Chemistry Department. Arachidonic acid was obtained from Nu-Chek Prep, Inc (Elysian, MN) , and the other fatty acid substrates, ␥-linolenic acid, docosatetranoic acid, eicosapentanoic acid, and docosapentanoic acid were obtained from Cayman Chemical (Ann Arbor, MI). For the preparation of radiolabeled inhibitors,4-[5-(4-methylphenyl)-3-(trifluoromethyl-4-bromo)-1H-pyrazol-1-yl]-benzenesulfonamide and 4-[3-(4-bromophenyl)-5-methyl-isoxazol-4-yl]-benzenesulfonamide ( Fig. 1) were treated with tritium gas in the presence of a palladium catalyst to obtain celecoxib tritiated at the 4-position of the pyrazole ring ([ 3 H]celecoxib; specific radioactivity, 3 Ci/mmol) and valdecoxib labeled at the 4-position of the 3-position benzene ring ([ 3 H]valdecoxib; specific radioactivity, 10 Ci/mmol), respectively.
Enzyme Preparation. COX-1 purified from sheep seminal vesicles and recombinant murine COX-2 expressed in insect cells was obtained as described previously (Gierse et al., 1999) . Briefly for COX-1, sheep seminal vesicles were homogenized into 50 mM TrisHCl, pH 8.0, 1 mM diethyldithiocarbamate (DEDTC), 1 mM EDTA, and 0.01% sodium azide and then centrifuged at 10,000g to remove cell debris. The supernatant was centrifuged at 200,000g to collect the microsomal fraction, which was washed once with homogenization buffer containing 115 mM sodium perchlorate and then extracted with 1.5% decyl-maltoside (C10M). The extract was centrifuged, and the resulting supernatant was concentrated by ultrafiltration using a 30-kDa molecular mass cutoff membrane and applied to a Sephacryl S-300 (Amersham Biosciences, Piscataway, NJ) gel filtration column equilibrated with 50 mM Tris-HCl, pH 8.0, 0.1 mM DEDTC, 0.1 mM EDTA, and 0.15% C10M. Protein fractions were eluted and then applied to a DEAE Trisacryl (Biosepra, Marlborough, MA) anion exchange column equilibrated with 20 mM TrisHCl, pH 8.0, 0.1 mM DEDTC, 0.1 mM EDTA, and 0.15% C10M. The column was developed with the same buffer, adjusted to pH 5.3. Active fractions were applied to an Ultragel ACA 54 (Biosepra) gel filtration column equilibrated with 20 mM potassium phosphate, pH 7.4, 0.1 mM DEDTC, 0.1 mM EDTA, and 0.3% n-octyl ␤-D-glucopyranoside. The final material was pooled and stored at Ϫ80°C until use.
Baculovirus-infected insect cells expressing recombinant murine COX-2 were suspended in 25 mM Tris-HCl, pH 8.0, 0.25 M sucrose, 1 mM DEDTC, and 1 mM EDTA, washed once, and extracted into the same buffer containing 1.5% C10M. The extract was centrifuged at 28,000g for 30 min, then applied to a Macro-Prep High-Q (Bio-Rad, Hercules, CA) anion exchange column equilibrated with 25 mM TrisHCl, pH 8.0, 0.1 mM DEDTC, 0.1 mM EDTA, and 0.15% C10M and eluted with a linear gradient to 0.3 M NaCl. Fractions were concentrated by ultrafiltration using a 30-kDa molecular mass cutoff membrane and applied to a S-200 Sephacryl gel filtration column equilibrated with 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1 mM DEDTC, 0.1 mM EDTA, and 0.3% n-octyl ␤-D-glucopyranoside. The active fractions were pooled and stored at Ϫ80°C until further use.
Antibody Preparation. COX-1 murine monoclonal antibody M584-7f4 and COX-2 murine monoclonal antibody R6 were affinity purified using protein-A agarose. To cell culture supernatants, sodium borate was added to 100 mM and pH adjusted to 8.9 with NaOH. These were then passed over a protein-A agarose column (Repligen, Needham, MA) equilibrated with PBS. Initially, the column was washed with 3 M NaCl, 100 mM sodium borate, pH 8.9, then by 3 M NaCl, 10 mM sodium borate, pH 8.9. The antibodies were eluted with 100 mM glycine, pH 3.0. Fractions were immediately pH neutralized with the addition of 1/10 (v/v) 1 M Tris-HCl, pH 8.1. The antibodies were then dialyzed against PBS and stored at Ϫ80°C until use.
COX-2 Mutagenesis and Expression. Site-directed mutagenesis (Val523Ile, Tyr355Ala, Arg120Ala, Arg120Asp, Arg120Gln, and His207Ala) and Val523Ile, Arg513His, Val434Ile (IHI) mutagenesis on a murine COX-2 pBlueScript(ϩ) vector (Stratagene, La Jolla, CA); subcloning into the mCOX-2 pVL1393 baculovirus expression vector (BD Biosciences Pharmingen, San Diego, CA); and expression by homologous recombination with Baculogold vector (BD Biosciences Pharmingen) in SF-9 cells (Novagen, Madison, WI) was performed as described previously (Rowlinson et al., 1999) . Purification of the COX-2 mutants was performed similarly to that described above for the native murine COX-2 enzyme.
Binding Assay. COX-1 or COX-2 specific antibodies (M584-7f4 or R6, respectively) at 10 g/ml in 100 mM NaHCO 3 , pH 8.2, were coated (100 l/well) onto 96-well Immulon 2 microtiter plates (Dynex Technologies Inc., Chantilly, VA) by incubating overnight at room temperature in a humidified chamber. The coated plates were washed with Dulbecco's phosphate-buffered saline, without CaCl 2 and MgCl 2 , pH 7.4 (D-PBS; Invitrogen, Carlsbad, CA) and then treated with a blocking reagent consisting of 10% skim milk in molpharm.aspetjournals.org D-PBS (0.2 ml) for 90 to 120 min at 37°C to decrease nonspecific binding to the plate. The coated and blocked plates were washed, COX enzyme was added at 20 to 35 g/ml in 50 l of binding buffer (100 mM Tris, 1 M hemin, pH 8.0), and then incubated at room temperature for 60 to 120 min. Finally, these antibody-captured, enzyme-coated plates were washed with D-PBS and aspirated to dryness immediately before the binding assay.
For the binding assay, the enzyme-coated plate wells contained 85 l of binding buffer, 5 l of dimethyl sulfoxide, and 10 l of radiolabeled ligand ( 3 H]celecoxib (0.9-350 nM) were added. Then, after a 2-to 3-h period of incubation, the wells were aspirated, rapidly washed (Ͻ2 s) with 250 l of ice-cold D-PBS, and bound radioligand was quantitated. Data were best fit to the equation (
where (RL) is the amount of bound radiolabeled ligand, (R) t is the total enzyme concentration, L is the ligand concentration, and K D is the equilibrium dissociation constant. For dissociation time-course experiments, the enzyme was initially incubated with radiolabeled ligand for 120 min. To initiate dissociation, the wells were aspirated, and 150 l of excess unlabeled ligand (10 M) was added. After various periods of time, the dissociated radiolabeled compound and the excess unlabeled compound were removed, and the remaining bound radioligand was quantitated. Data were best fit to the equation (RL) ϭ (RL) 0 e (Ϫk ϫ t) where t is time and k is the dissociation rate constant. For association time-course experiments, after the addition of 3 H-labeled ligand, the incubations were halted at various time points by aspiration, rapidly washed, and bound radioactivity was quantitated. Data were best fit using an equation described by Rodbard and Weiss (1973) . Lastly, for the competitive binding assays, a 96-well dilution plate was used to initially make dilutions of the compound. To each of these different concentrations was added a trace amount of 3 H-labeled ligand; then, the complete mixture of unlabeled test compound and trace radiolabel was added to the enzyme-coated plate. This method would ensure that there was no preincubation of either the test compound or the radiolabeled ligand with the enzyme. K i values were derived from the concentration of competing compound that inhibited 50% of the binding observed in the absence of any inhibitor (IC 50 ) using the equation of Cheng and Prusoff (1973) . In assays in which different COX substrates were examined, the His207Ala variant of COX-2 was employed. In addition, heme was omitted from the assay buffer. Other investigators have shown that the His207Ala variant is devoid of peroxidase activity (Landino et al., 1997) . Data were transformed into logit-log analysis, and K i values are reported. In all experiments, bound 3 H-labeled ligand was eluted from the plate using 10% SDS in D-PBS and quantitated using liquid scintillation counting. All assays were done at room temperature unless otherwise specified. Nonspecific binding was defined as the residual binding in the absence of enzyme. 3 H]valdecoxib were tested for their ability to specifically bind to COX-1 and COX-2 enzymes that had been captured by non-neutralizing antibodies onto a microtiter plate. Under these conditions, enzymatic analysis of both the COX-1-and COX-2-coated plates, using arachidonic acid as substrate, revealed that the plates did contain active enzyme sufficient to produce measurable quantities of prostaglandin E 2 (PGE 2 ); COX-2 produced 1.4 ng/ml, whereas COX-1 produced 0.9 ng/ml PGE 2 in 10 min at room temperature with 10 M arachidonic acid. The production of PGE 2 by COX-1 on the coated plate could be inhibited by indomethacin, and a pharmacological analysis of COX-1 and COX-2 enzymes from both sheep and murine sources revealed similar inhibitory profiles (data not shown). Figure 2 , H]valdecoxib to COX-2 is saturable, reversible, specific, and of high affinity, the pharmacological relevance of this binding site remained uncertain. Consequently, we tested the ability of known COX-2 inhibitors and substrates to compete for binding of these radioligands. Some of these inhibitors have been described as exhibiting time-dependent characteristics in enzymatic assays. In the binding assay, both the cold competitor test compound and radiolabeled ligands were added simultaneously to the enzyme. When substrates were tested as competitors, we used the His207Ala mutant of the wild-type COX-2, which is devoid of peroxidase activity; thus, the cyclooxygenase reaction is indirectly prevented as well (Landino et al., 1997 [ 3 H]valdecoxib to COX-2. In general, each NSAID seemed to maximally inhibit more than 90% of the radioligand binding, with logit-log slopes approximating one. Furthermore, the rank-order potency for inhibition of radioligand binding to COX-2 roughly corresponds to that rank-order potency observed for inhibition of COX-2 mediated PGE 2 production (Gierse et al., 1999 Various studies have shown that specific residues of COX-2 are critical for the inhibitory potency of diarylheterocyclics and may be, in part, responsible for the selectivity of these inhibitors relative to COX-1. Consequently, specific residues within the main channel of COX-2 were mutated and the resulting mutated COX-2 enzymes tested for their ability to bind [ 3 H]celecoxib and [ 3 H]valdecoxib. Diarylheterocycle inhibitors of COX-2 interact with residues in the COX side pocket, three of which (Val523, Arg513, and Val434) differ between COX-1 and COX-2. To closely mimic this region of COX-1, these residues in COX-2 were mutated to the corresponding amino acids of COX-1; isoleucine, histidine, and isoleucine, respectively (variants Val523Ile and IHI). Tyr355 is a unique residue in the cyclooxygenase active site because it lies at the entrance to both the side pocket and the main channel. To evaluate its impact on inhibitor binding, Tyr355 was mutated to alanine (Tyr355Ala). Because Arg120 has been shown to form an ion pair with all NSAIDs containing a carboxylate group that have been visualized crystallographically (Picot et al., 1994; Kurumbail et al., 1996) and is thought to form an ion pair with arachidonic acid (Bhattacharyya et al., 1996; Kiefer et al., 2000; Malkowski et al., 2000) , we also examined mutants of Arg120 (Arg120Asn, Arg120Ala, and Arg120Gln) to explore their effect on the binding of After this initial incubation period, the free unbound radioligand was aspirated off and 150 l of excess cold ligand (10 M) was added to initiate the dissociation time course. Then, at various times, the wells were aspirated and the remaining amount bound was determined using liquid scintillation counting. Data shown are the mean Ϯ S.E.M. from at least three experiments each performed in triplicate. strated specific binding to all of the COX-2 mutant enzymes. In general, mutation of residues near the entrance to the main channel (Tyr355 and Arg120) significantly increased the association rate of both [ 3 H]celecoxib and [ 3 H]valdecoxib binding similarly (6-to 11-fold). Also, mutating Arg120 to alanine, glutamine, or asparagine increased the dissociation rate approximately 2-to 5-fold; the overall net effect of these increases was a slight, ϳ3-fold increase in affinity. On the other hand, the side pocket mutations tended to more greatly affect the dissociation rate than the association rate, with a greater effect on 
Results

Discussion
The ability to develop selective inhibition of COX-2 with diarylheterocycle compounds has proven beneficial therapeutically. These compounds significantly reduce the risk of gastric ulcerations typically observed with NSAIDs (Simon et al., 1999; Bombardier et al., 2000) . In this manuscript, we directly characterized the binding of two diarylheterocycle compounds, [
3 H]celecoxib and [ 3 H]valdecoxib, to COX-2 and further established their selective nature. We demonstrated that they bind in a saturable, highly specific, and readily reversible manner to a single site that correlates pharmacologically with the cyclooxygenase active site of COX-2. Furthermore, we have confirmed the highly selective COX-2 inhibitor profile of [ 3 H]celecoxib and [ 3 H]valdecoxib by demonstrating their inability to bind specifically to COX-1 within limits of the assay used. Thus, the radioligand binding assay described here could be used to screen the binding potency of potential COX-2 inhibitors.
In Wild-type COX-2 or the specified mutant enzyme was captured by an antibody onto a plate and then saturation, dissociation, and association type binding experiments performed as described under Materials and Methods. Data are expressed as the mean Ϯ S.E.M. from the number of experiments shown in parentheses. Wild-type COX-2 or the specified mutant enzyme was captured by an antibody onto a plate, and then saturation, dissociation, and association binding experiments were performed as described under Materials and Methods. Data are expressed as the mean Ϯ S.E.M. from the number of experiments shown in parentheses. rate and a very slow dissociation rate from wild-type COX-2. The dissociation rates, as well as the association rates, we obtained are in close agreement to those reported by Lanzo et al. (2000) for the diarylheterocycle SC-299 (k Ϫ1 ϭ 15 ϫ 10 Ϫ3 / min and k ϩ1 ϭ 7.2 ϫ 10 6 /M/min). Both of these kinetic rates for [
3 H]celecoxib and [ 3 H]valdecoxib were increased by the mutation at Arg120 to a smaller amino acid; the association rate was significantly more affected at nearly 10-fold. Mutation of Arg120 to smaller neutral amino acids may provide more flexibility at the entrance to the main channel by disrupting the salt bridge between Arg120 and Glu524, potentially expanding the entrance to the main hydrophobic channel. This could allow more rapid access to the diarylheterocycle-binding site and give rise to the observed increase in association rate. If the entrance has been perturbed by these mutants, the increase in association rate may be somewhat offset by a more rapid dissociation of the ligand from the binding site because of the loss of van der Waals contacts and loss of the potential ion pair with Arg120. The overall net effect being a slight increase in affinity of both H]celecoxib only 2-to 4-fold over wild-type COX-2. The difference in the magnitude of the effect may be related to the decrease in volume of the side pockets of the mutants, which may prevent the optimal binding conformation of the inhibitors from being obtained. So et al. (1998) reported that the binding of a diarylheterocyclic inhibitor, SC-57666, to a Tyr355Phe mutant of COX-2 was rapidly reversible, in contrast to the slow dissociation from wild-type COX-2. Similarly, we found the Tyr355Ala mutant increases both We also observed a 10-fold increase in the association rate with the Tyr355Ala mutant, suggestive of less steric hindrance at the entrance and easier access to the binding site. Thus, the tyrosine-toalanine mutation at position 355 may have the effect of enlarging both the entrance to the main channel and the entrance into the side pocket. These kinetic results are consistent with previous reports of the importance of the side pocket in diarylheterocycle potency and selectivity Guo et al., 1996; Wong et al., 1997 3 H]celecoxib. These additional contacts between valdecoxib and the side pocket may make that inhibitor more sensitive to amino acid differences in the side pocket between COX isoforms, perhaps contributing to its increased selectivity relative to celecoxib.
We were unable to detect any reproducible specific binding of [ 3 H]celecoxib and [ 3 H]valdecoxib to COX-1 at the concentrations tested. However, because of the high degree of nonspecific binding we observed at the higher concentrations, we cannot exclude the possibility that these inhibitors may bind to COX-1 with extremely low affinity (K D Ͼ 1000 nM). This result is not surprising given the low potency for inhibition of COX-1 mediated PGE 2 production that these compounds display . Somewhat surprisingly, the triple mutant of COX-2, IHI, which should mimic COX-1 at the critical side pocket residues, produced only 3-and 17-fold decreases in affinity of [ 3 H]celecoxib and [ 3 H]valdecoxib, respectively. These data suggest that other important differences between COX-1 and COX-2, besides the side pocket, enhance the selectivity of these diarylheterocycle inhibitors. One potential area influencing selectivity is near the entrance to the main hydrophobic channel, where Arg120, Tyr355, Glu524, and helix D reside. When these residues have been mutated, several studies described dramatic effects on substrates and the potency of inhibitors (Greig et al., 1997; Rieke et al., 1999) , suicide inactivation (Bhattacharyya et al., 1996) , and allosteric activation (So et al., 1998) . Lanzo et al. (2000) have described this area as a lobby region in which two or three stages of interaction with inhibitors could occur.
In this report, we have characterized the binding of celecoxib and valdecoxib to wild-type COX-2 and various mutants of COX-2. However, we could not obtain any specific binding to wild-type COX-1 using assay conditions that demonstrate high-affinity saturable binding to COX-2. Using a COX-2 mutant (IHI) in which selective substitutions were designed to hinder side pocket accessibility and mimic COX-1, we could demonstrate specific binding. These data suggest that the reduced side pocket volume of COX-1 is not the only source of diarylheterocycle selectivity. Additional features of COX-2, besides the side pocket, must exist that impact the specificity and selectivity of COX-2 binding by this class of inhibitors. We believe that this radioligand binding assay offers both a unique perspective to characterize the binding of celecoxib and valdecoxib and a rapid means in which potential COX-2 inhibitors may be tested for their potency.
